公开(公告)号：US12049512B2

公开(公告)日：2024-07-30

申请号：US16921154

申请日：2020-07-06

Applicant: GENMAB B.V.

Inventor： Paul Parren ,  Frank Beurskens ,  Rob N. De Jong ,  Aran Frank Labrijn ,  Janine Schuurman

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/36 ,  C12P21/08 ,  A61K39/00 ,  C07K1/00

CPC classification number: C07K16/2896 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/36 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92

Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.

公开(公告)号：US11180572B2

公开(公告)日：2021-11-23

申请号：US14413178

申请日：2013-07-05

Applicant: GENMAB B.V.

Inventor： Rob N. De Jong ,  Frank Beurskens ,  Paul Parren ,  Aran Frank Labrijn ,  Janine Schuurman ,  Arjen Vlug ,  Sandra Verploegen

IPC: C07K16/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  C07K16/40 ,  C07K16/32 ,  C07K16/10 ,  C07K16/36 ,  C07K16/12 ,  A61K39/00

Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.

公开(公告)号：US20150175707A1

公开(公告)日：2015-06-25

申请号：US14413178

申请日：2013-07-05

Applicant: GENMAB B.V.

Inventor： Rob N. De Jong ,  Frank Beurskens ,  Paul Parren ,  Aran Frank Labrijn ,  Janine Schuurman ,  Arjen Vlug ,  Sandra Verploegen

IPC: C07K16/40 ,  C07K16/12 ,  C07K16/28

Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.

Abstract translation: 本发明涉及包含不同于存在于人IgG1中的三个不同位置的氨基酸的二聚体蛋白质。 所述二聚体蛋白中的六个能够在溶液中形成六聚体结构。

公开(公告)号：US12173076B2

公开(公告)日：2024-12-24

申请号：US16482747

申请日：2018-02-12

Applicant: GENMAB B.V.

Inventor： Frank Beurskens ,  Marije Overdijk ,  Annieck M. Diks ,  Rob De Jong ,  Kristin Strumane ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/28 ,  C07K16/10

Abstract: As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.

公开(公告)号：US20230212301A1

公开(公告)日：2023-07-06

申请号：US18055362

申请日：2022-11-14

Applicant: Genmab B.V.

Inventor： Andreea Ioan ,  Frank Beurskens ,  Rob N. de Jong ,  Janine Schuurman ,  Esther C. W. Breij ,  Isil Altintas ,  Pauline L. de Goeje ,  David Satijn ,  Peter Boross ,  Ugur Sahin ,  Friederike Gieseke ,  Alexander Muik ,  Kristina Schödel

IPC: C07K16/28 ,  C07K16/42 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/4208 ,  A61K2039/505

Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.